An observational study in Epistaxis, sponsored by University Hospital, Grenoble. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-24.
Sponsored by University Hospital, Grenoble · Observational
We study all patients admitted to the Emergency Department in the Institution between 01/2022 and 07/2023. The information about the recurrence of nose bleeding was searched on their medical file and by calling the patient to confirm ou get the information. Thus, several potentiel risk factors were studied.
The relation between recurrence and those factors were studied at first individually and then all the significant ones were analyzed with a multivarious statistical test.
We study all patients admitted to the Emergency Department in the Institution between 01/2022 and 07/2023. The information about the recurrence of nose bleeding was searched on their medical file and by calling the patient to confirm ou get the information. Thus, several potentiel risk factors were studied : oral anticoagulants, sex, INR, anti-platelets drugs, diabetes, obesity, arterial hypertension, heart failure, hemoglobin at the admission, history of chronic rhinosinusitis, appointment with an ENT during the acute bleeding, sleep apnea, age, anatomic abnormality, recent surgery within 2 months, previous admission within 30 days in the emergency department, nasal trauma.
The relation between recurrence and those factors were studied at first individually and then all the significant ones were analyzed with a multivarious statistical test.
This study aim to provide a pronostic score of recurrence that can happen after the 3 fisrt weeks after the event. When a recurrence happens before 3 weeks, this was considered to be a non control of the bleeding episode.
This score will be then tested on our cohort to evaluate specificity and sensibility.
96 studies on the registry are indexed under Epistaxis; 22 are open to participants now.
This study's planned enrollment of 145 is above the median of 71 across 12 observational studies indexed under Epistaxis.
Browse Epistaxis studies →University Hospital, Grenoble is the lead sponsor of 837 studies on the registry; 207 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All the patientswho are admitted at the emergency department between 01/2022 and 07/2023
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Evaluation of recurrence epistaxis during the year after a first episode
Survival without bleeding
Measuring the delay between the first epistaxis and a recurrence.
Time frame: 1 year
Plan to share: No
Start is estimated for Nov 2024; primary completion for Mar 2025, 3 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Grenoble →